Open Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
BBD Reference Set Application: Jeffery Marks-Duke (2015)	Leading	11	0
Detection of Serum Markers of Breast Cancer by SELDI	Coordinating	0	0
Development of FISH-based assay for early detection of high grade cervical dysplasia	Involved	0	0
Early Detection of Breast Cancer Using Autoantibody Markers	Involved	0	0
Expression based markers for breast cancer detection	Leading	0	1
Identification of biomarkers for ER+ breast cancer	Involved	0	0
Standard Specimen Reference Set: Breast Cancer and Imaging	Leading	0	3
The Early Detection Research Network: Biomarker Reference Laboratories	Involved	0	0
Validation of Early Detection Ovarian Cancer Biomarkers (Team Project)	Involved	149	0

Closed Protocols

Protocol Name	Investigatory Role	Biomarkers	Data Collections
Benign Breast Disease Team Project	Involved	25	1
Biomarker Detection Using NAPPA Tumor Antigen Arrays	Involved	28	0
Breast Reference Set Application: Anu Mathew-Meso Scale (2012)	Involved	90	0
DCIS Team Project	Involved	6	1
EDRN Resource Network Exchange	Involved	0	0
PTM Microarray: Request for Year 3 Set-Aside Funds	Involved	0	0
Triple Negative Breast Cancer Team Project	Involved	147	0
Year 2 Collaborative Project - UCSF and Battelle PNWD	Involved	0	0

Publications

Publication Name	PubMed ID	Journal
Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression.	15082792	Mol Cell Biol
Analysis of methylation-sensitive transcriptome identifies GADD45a as a frequently methylated gene in breast cancer.	15735726	Oncogene
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction.	21254049	Cancer
Do serum biomarkers really measure breast cancer?	19476629	BMC Cancer
Estrogen receptor alpha (ESR1) mutant A908G is not a common feature in benign and malignant proliferations of the breast.	15034868	Genes Chromosomes Cancer
Evaluation of expression based markers for the detection of breast cancer cells.	16319979	Breast Cancer Res Treat
Expression signatures of TP53 mutations in serous ovarian cancers.	20504346	BMC Cancer
Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.	16603642	Mol Cancer Res
Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia.	21852960	PLoS Genet
High throughput detection of M6P/IGF2R intronic hypermethylation and LOH in ovarian cancer.	16432260	Nucleic Acids Res
Inactivation of the MAL gene in breast cancer is a common event that predicts benefit from adjuvant chemotherapy.	19208741	Mol Cancer Res
Isogenic normal basal and luminal mammary epithelial isolated by a novel method show a differential response to ionizing radiation.	17409405	Cancer Res
Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.	20473856	Int J Cancer
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.	19318476	Clin Cancer Res
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care.	19224362	Breast Cancer Res Treat
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.	15897565	Clin Cancer Res
Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.	21586622	Cancer Epidemiol Biomarkers Prev
Pooling of case specimens to create standard serum sets for screening cancer biomarkers.	17301268	Cancer Epidemiol Biomarkers Prev
Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers.	15598772	Cancer Epidemiol Biomarkers Prev
Role of eotaxin-1 signaling in ovarian cancer.	19351767	Clin Cancer Res
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.	18474099	Breast Cancer Res
TAFII70 isoform-specific growth suppression correlates with its ability to complex with the GADD45a protein.	15328371	Mol Cancer Res
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.	21501600	Biochem Pharmacol
The type III TGF-beta receptor suppresses breast cancer progression.	17160136	J Clin Invest
Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissues.	23274563	Gynecol Oncol
Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction.	18197258	PLoS One

Interests

Cell cycle regulation in breast cancer

I am particularly interested in the process by which cells accumulate an abnormal content of DNA or aneuploidy. DNA damage must occur, either spontaneously or induced, but in conjunction, checkpoint controls must be abrogated to allow for the cell to maintain this aberration. We are currently studying the molecular events surrounding the abrogation of the g2 checkpoint in breast cancer and normal breast epithelium. In particular, we are investigating the role of BRCA1 in this process.

To update protocols, publications, biomarkers, or science data, please contact the Data Management and Coordinating Center.

Site

Duke University Medical Center

Degree(s)

Ph.D.

Email

jeffrey.marks@duke.edu

Fax

(919) 681-6291

Person ID

1009

EDRN Title

EDRN Associate Member

Note

To update contact information, please visit the Data Management and Coordinating Center .